chugai pharmaceutical and a-cube announce agreement

conversesoilΒιοτεχνολογία

3 Δεκ 2012 (πριν από 4 χρόνια και 6 μήνες)

215 εμφανίσεις

Chugai Press Release

1

3/16/2013


A
-
CUBE

ANNOUNCE
S

AGREEMENT

WITH CHUGAI PHARMACEUTICAL
CO., LTD



BELMONT

CA, USA,
December 15
th, 2010 (BUSINESS WIRE)
--

A
-
CUBE

Inc., today
announced that it has

reached an agreement with Chugai Pha
rmaceutical Co. Ltd
, Japan.
Under the agreement, the two
parties w
ill collaborate on develop
ing

the next generation
of antibody therapeutics

using A
-
CUBE's proprietary in silico algorithms.



We are very pleased to start
this collaboration with
Chugai
, Japan's leading

pharmaceutical company
,

and a
leader in mono
clonal
antibody
therapeutics," stated

Nobu
Ota PhD, Founder and President of A
-
CUBE
.
"This is the start of a new strategic
initiative by A
-
CUBE

to seek long
-
term collaborations with expert partners."


“A
-
CUBE

brings very ori
ginal approaches that are compli
m
entary to our own
capabilities,” stated

Hisafumi Okabe

PhD,
Vice President, General Manager of Research
Division of

Chugai.

"We are expecting that they

can make contributions to

our challenge
in this much competitive area of research
."


A
-
CUBE Inc., is a
venture capital backed company funded by JAIC and yet2.com, which
uses proprietary in silico algorithms to predict and monetize novel drug targets related to
blockbuster drugs. It has used this to develop a preclinical therapeutic monoclonal
antibody for c
ancer and other diseases.


Chugai P
harmaceutical, specializes in prescription pharmaceuticals and based in Tokyo,
is one of Japan's leading research based pharmaceutical companies with strengths in
biotechnology products. Since the start of the strategic
alliance with Roche in October
2002, Chugai is actively involved in prescription pharmaceutical R&D activities in Japan
and abroad as an important member of the Roche Group. Specifically, Chugai is working
to develop innovative products with global applica
tions, focusing on the disease areas of
oncology, renal disease, and bone and joint. In Japan, Chugai's research facilities in
Gotemba and Kamakura are collaborating to develop new pharmaceuticals and Ukima is
conducting research for technology development

for industrial production.
Overseas,
Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development
activities in the United States and Europe. The consolidated sales in 2009 of Chugai
totaled 428.9 billion yen and the operating profit was

82.6 billion yen. We are aiming at
the consolidated sales of 460 billion yen and operating profit of 80 billion yen in 2012,
as stated in the mid
-
term business plan "Sunrise 2012". Additional information is
available on the Internet at http://www.chugai
-
pharm.co.jp/.

JAIC America is a venture capital firm based in the Silicon Valley, focused on early stage
investments in the Mobile/Communications, Digital Media, Life Science and Cleantech
sectors.

JAIC is

part of Japan Asia Investment Co. (JAIC) group, a
premier venture
capital and private equity firm listed on the Tokyo Stock Exchange with $1.3 Billion
assets under management. JAIC America was established in January 1999 and since then
Chugai Press Release

2

3/16/2013

we have actively invested in the US
. JAIC has

successfully created sev
eral US
-
Japan
cross
-
border business models and have the know
-
how to bring US technologies, services,
and business models to Japan
. JAIC tries

to keep the right "management team
-

investor"
balance to engender a productive

outcome
.

For more information, vi
sit
http://www.jaicamerica.com
.

yet2.com

is a venture capital firm that has backed A
-
CUBE, and
provides intellectual
property consulting and licensing services to world
-
class clients around the globe.
Yet2.com Inc and its online marketplace were founded i
n 1999 to promote Open
Innovation, with original investments from Siemens, Bayer, Honeywell, DuPont, Procter
& Gamble, Caterpillar, and NTT Leasing. The privately held company has offices in the
United States, Europe, and Japan. The web site now has over 1
20,000 registered
marketplace users including many of the Fortune 500 and over 16,000 smaller technology
companies. In addition to its core team,
yet2.com

has created a wide network of Open
Innovation partners covering many of the technology
-
rich countries

around the world as
well as relationships with open innovation organizations, technical expert networks, SME
networks, technical magazines, online technical communities, and technology brokers.
These provide market
-
wide access to technologies and needs in

countries such as Russia,
China, India, Korea, Brazil, South Africa, Japan, the US, and the EU. For more
information, visit
www.yet2.com

or contact Tim Bernstein 1
-
781
-
972
-
0600.


SOURCE: A
-
CUBE, Inc.


Company Contact
:

Nigel Ten Fleming PhD,

Chief Executive Officer

A
-
CUBE, Inc.

530 Harbor Blvd

Belmont, CA, 940
0
2

Tel: (415)
-
515
-
7614

Email:
Nigel@ACubeinsilico.com
.

Website:

http://www
.acube.cc